Identify
VOD

Identify VOD promptly

VOD is one of many complications that can occur in patients undergoing HSCT.1

Cases vary in severity and require careful monitoring as severe VOD is associated with a mortality rate of over 80%.2

While the incidence of VOD varies between studies,2 with careful management, even severe VOD can be expectable, predictable and survivable.3-5

Scroll to view the steps to making an accurate diagnosis, and click to explore the content.

This treatment journey is designed by Jazz Pharmaceuticals for illustrative purposes.

01 /

Risk assessment

Risk assessment is vital in facilitating prompt diagnosis and early treatment of severe VOD.6,7

Risk factors for developing VOD fall into three distinct categories (as defined by the EBMT):6

Patient- and disease-related risk factors – e.g. older age; advanced disease; Karnofsky score <90%; genetic factors; metabolic syndrome; thalassaemia; norethisterone use in women

Transplant-related risk factors – e.g. unrelated or HLA-mismatched donor; regimen-dependent risks, such as oral or high-dose busulfan, or high-dose TBI or myeloablative conditioning; non-T-cell–depleted transplant or second HSCT

Hepatic-related risk factors – e.g. cirrhosis; active viral hepatitis; abdominal/hepatic irradiation; specific previous drug use including hepatotoxic agents; elevated transaminases (>2.5 ULN) or serum bilirubin (>1.5 ULN)

For more expert videos on risk assessment, please visit the Resources page.

02 /

Daily monitoring

Best practice maintains that daily, strict monitoring is essential for detecting early signs and symptoms of VOD.3,8,9

The following parameters should be monitored and recorded:

  • Abdominal girth
  • Weight
  • Tenderness
  • Bilirubin levels

In addition, continuously monitor: Fluids in/out, urea and electrolytes, blood tests, coagulation, liver function.

Immediately report to team/senior doctors on duty if you observe:

  • Weight gain
  • Increased abdominal tenderness
  • Fluid retention
  • Increased abdominal girth

For more expert videos on monitoring for the signs and symptoms for VOD, please visit the Resources page.

03 /

Diagnosis of vod

The diagnostic criteria for VOD can identify a differential diagnosis.6

Traditional criteria:

  • The Baltimore and modified Seattle criteria are traditionally used to diagnose VOD in both children and adults10–12
  • Both require the presence of VOD to be within 21 days of HSCT10–12
  • The Baltimore criteria also require elevated bilirubin levels (≥2 mg/dL [34 µmol/L])10

The evolving criteria for earlier diagnosis and treatment:

  • New clinical data show that the use of criteria, which do not require elevated bilirubin levels for classical VOD, may allow for earlier identification and diagnosis of VOD10–13
  • New clinical data also showed VOD was diagnosed both before and after Day 21 in both age groups13
  • Therefore, there is a need to strictly monitor the possibility of VOD at any time after HSCT, even in the absence of elevated bilirubin levels13

 

See the Baltimore and modified Seattle diagnostic criteria

Late cases of VOD have been reported (>21 days)13 and are included in the EBMT diagnostic criteria for adults.6

See the EBMT diagnostic criteria

For more expert videos on diagnosing VOD, please visit the Resources page.

04 /

Severity grading

The EBMT severity grading can aid in differential diagnosis, enhanced vigilance and prompt intervention.6

 

The guiding principles for severity grading are:6

Principle 1

Determine severity from patient presentation

Classification based on the category for which they fulfil ≥2 criteria

Principle 2

Take into account criteria fulfilled in other categories

Classification based on ≥2 criteria across two different categories fulfilled?
Classified in the most severe category

Principle 3

Consider risk factors

Classification based on ≥2 mild or ≥2 moderate criteria and ≥2 risk factors for VOD?
Move up a grade

While severe and very severe VOD decreases OS rates compared with mild or moderate VOD, prompt intervention with Defitelio® can improve survival.14,15

Use this poster as a handy reminder of the severity grading criteria and principles.

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at: https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at: AEreporting@jazzpharma.com

Defitelio® is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.